HALO vs. QGEN: Halozyme Therapeutics vs. Qiagen Stock Comparison
How do Halozyme Therapeutics (HALO) and Qiagen (QGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Halozyme Therapeutics (HALO) and Qiagen (QGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while QGEN is classified in Life Sciences Tools & Services.
| Profile Item | HALO | QGEN |
|---|---|---|
| Name | Halozyme Therapeutics Inc. | Qiagen N.V. |
| Country/Region | United States | Netherlands |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 11.81 billion USD | 10.39 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | March 16, 2004 | June 28, 1996 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | HALO | QGEN |
|---|---|---|
| Total Return (1Y) | 50.94% | 17.09% |
| Total Return (3Y, Annualized) | 41.08% | 10.44% |
| Total Return (5Y, Annualized) | 21.68% | -0.72% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | HALO | QGEN |
|---|---|---|
| Volatility (1Y, Annualized) | 41.19% | 35.52% |
| Beta (5Y) | 0.96 | 0.56 |
| Max Drawdown (5Y) | -49.06% | -41.97% |
| Avg. Volume (3M) | 2.29M | 3.68M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | HALO | QGEN |
|---|---|---|
| Sharpe Ratio (1Y) | 1.13 | 0.36 |
| Sortino Ratio (1Y) | 1.78 | 0.60 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Halozyme Therapeutics (HALO) at 216.38% is the standout with ROE above its industry range; Qiagen (QGEN) at 10.81% also sits in the top quartile.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
216.38%
- HALO
- 216.38%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.81%
- Max
- 109.18%
- QGEN
- 10.81%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Halozyme Therapeutics (HALO) at 26.93% and Qiagen (QGEN) at 18.20% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.93%
- HALO
- 26.93%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.20%
- QGEN
- 18.20%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Halozyme Therapeutics (HALO) at 59.84% and Qiagen (QGEN) at 27.75% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
59.84%
- Max
- 83.12%
- HALO
- 59.84%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.75%
- Max
- 83.12%
- QGEN
- 27.75%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | HALO | QGEN |
|---|---|---|
| ROE (TTM) | 216.38% | 10.81% |
| ROA (TTM) | 22.42% | 5.68% |
| Net Margin (TTM) | 26.93% | 18.20% |
| Operating Margin (TTM) | 59.84% | 27.75% |
| Gross Margin (TTM) | 77.74% | 67.06% |
Growth
Revenue Growth
Both Halozyme Therapeutics (HALO) at 37.55% and Qiagen (QGEN) at 5.65% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Qiagen (QGEN) at 409.76% clears its industry range for EPS growth, a much stronger earnings trajectory than Halozyme Therapeutics (HALO) at -25.36%, which is closer to a typical peer reading.
Growth Metrics
| Metric | HALO | QGEN |
|---|---|---|
| Revenue Growth (YoY) | 37.55% | 5.65% |
| Revenue Growth (3Y CAGR) | 28.38% | -0.81% |
| EPS Growth (YoY) | -25.36% | 409.76% |
| EPS Growth (3Y CAGR) | 21.14% | -0.19% |
Financial Strength
Current Ratio (MRQ)
Both Halozyme Therapeutics (HALO) at 3.88 and Qiagen (QGEN) at 2.63 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.88
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- HALO
- 3.88
- Q1
- 2.47
- Min
- 0.10
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- QGEN
- 2.63
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Qiagen (QGEN) carries debt-to-equity ratio of 0.47 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- HALO
- --
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.47
- Max
- 1.42
- Q3
- 0.65
- QGEN
- 0.47
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | HALO | QGEN |
|---|---|---|
| Current Ratio (MRQ) | 3.88 | 2.63 |
| Debt / Equity (MRQ) | -- | 0.47 |
| Net Debt / EBITDA | 1.90 | 1.08 |
Dividends
Dividend Yield (TTM)
Halozyme Therapeutics (HALO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a yield of 0.71%, ranking against industry peers normally.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.71%
- QGEN
- 0.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Halozyme Therapeutics (HALO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a payout of 18.21%, ranking against industry peers normally.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.21%
- QGEN
- 18.21%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | HALO | QGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.71% |
| Dividend Payout Ratio (TTM) | 0.00% | 18.21% |
Valuation
P/E Ratio (TTM)
Both Halozyme Therapeutics (HALO) at 25.91 and Qiagen (QGEN) at 27.21 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.91
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- HALO
- 25.91
- Q1
- 13.30
- Min
- 0.07
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.21
- Max
- 85.34
- Q3
- 43.46
- QGEN
- 27.21
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Halozyme Therapeutics (HALO) at 6.55 and Qiagen (QGEN) at 4.91 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- HALO
- 6.55
- Q1
- 3.01
- Min
- 0.01
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.91
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- QGEN
- 4.91
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Qiagen (QGEN) reports 2.99, ranking against industry peers normally.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-213.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- HALO
- -213.67
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.99
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- QGEN
- 2.99
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | HALO | QGEN |
|---|---|---|
| P/E Ratio (TTM) | 25.91 | 27.21 |
| P/S Ratio (TTM) | 6.55 | 4.91 |
| P/B Ratio (MRQ) | -213.67 | 2.99 |
| Free Cash Flow Yield (TTM) | 3.48% | 3.62% |